A low-cost SARS-CoV-2 rRBD ELISA to detect serostatus in ecuadorian population with COVID-19

4Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

Abstract

Laboratory diagnosis of the COVID-19 relies on RT-PCR to amplify specific fragments of SARS-CoV-2 genome. However, serological tests are required to determine the immune response elicited after infection. Here, we analyzed convalescent sera collected from positive individuals by RT-PCR to SARS-CoV-2 (n = 78), Zika (n = 20), dengue (n = 20), chikungunya (n = 54), intestinal parasites (n = 11), and HIV (n = 1), from different areas of Ecuador, with an in-house ELISA using a SARS-CoV-2 receptor binding domain recombinant (rRBD) antigen to detect IgG antibodies elicited by SARS-CoV-2 infection. Of the 78 samples positive for SARS-CoV-2 by RT-PCR, 73 showed high absorbance value compared with the cutoff and five were negative. All tested sera from other infections showed no reactivity. Sensitivity, specificity, positive predictive value, and negative predictive value were 93.6%, 100%, 100%, and 95.4%, respectively. This in-house anti-IgG rRBD ELISA offers an economic and simple alternative to determine IgG immune responses after SARS-CoV-2 infection.

Cite

CITATION STYLE

APA

Guevara, Á., Vivero, S., Nipaz, V., Guaraca, V., & Coloma, J. (2021). A low-cost SARS-CoV-2 rRBD ELISA to detect serostatus in ecuadorian population with COVID-19. American Journal of Tropical Medicine and Hygiene, 104(4), 1513–1515. https://doi.org/10.4269/ajtmh.20-1420

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free